Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Method...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 39; no. 26; pp. 2959 - 2961
Main Authors Tung, Nadine M., Zakalik, Dana, Somerfield, Mark R.
Format Journal Article
LanguageEnglish
Published 10.09.2021
Online AccessGet full text

Cover

More Information
Summary:ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Review-3
ObjectType-Feature-4
ObjectType-Instructional Material/Guideline-2
content type line 23
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.21.01532